MB3SBIO@EC2606A(18504.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
MB3SBIO@EC2606A
18504.HK
News
View More

Early Morning Trend | LUYE PHARMA retraces to the stage low, can sector linkage change the weakness?

LUYE PHARMA (2186.HK) has recently seen its stock price continue to decline, temporarily retracing to the previous low point area. The daily death cross signal is clear, and the short-term bearish atmosphere dominates the market. From a technical perspective, major indicators such as MACD and RSI are showing weakness, with the 5-day and 10-day moving averages continuing to decline, and the K-line combination leaning towards bearish, indicating ongoing market selling pressure. On the fundamental side, although LUYE PHARMA has launched some new drugs, the industry as a whole has entered a complex phase of stricter policy regulation, price reductions in medical insurance, and high R&D investments, which affects performance improvement in the short term due to various uncertainties. The overall performance of the pharmaceutical sector has seen a recent decline in participation enthusiasm, with major institutions preferring defensive industries or rotating into high-growth areas. In terms of sector linkage, the pharmaceutical sector is weak, with noticeable short-term capital outflows. LUYE PHARMA is constrained by the overall atmosphere, facing systemic adjustment pressure brought about by the industry's "collective bearish" sentiment. In the current sensitive range of the retracement phase, both institutions and short-term funds remain highly sensitive, with price fluctuations easily triggering sector resonance. For future trends, attention should be paid to whether the support at this low point is effective. If strong support is breached, short-term bearish signals may further strengthen; conversely, if funds provide support and lead to a reversal of indicators, there may be a technical rebound in the short term. Investors should strictly control risks, primarily adopting a wait-and-see approach when the bottom is unclear, and if making tentative layouts, set appropriate stop-loss levels

Technical Forecast·
HK
02186
-2.11%
HK
01530
-2.59%
Technical Forecast·
HK
02186
-2.11%
HK
01530
-2.59%

CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

Tip Ranks·
SZ
159102
-2.19%
SH
513700
-2.08%
SZ
159316
-2.10%
Tip Ranks·
SZ
159102
-2.19%
SH
513700
-2.08%
SZ
159316
-2.10%

CITIC International expects that the release of the value of 707 drugs will drive 3SBIO upward

The research report from China Merchants Bank International indicates that the drug development program 707/PF'4404, a collaboration between Pfizer and 3SBIO, has progressed beyond expectations, with four global Phase 3 clinical studies expected to start in 2026. This drug is anticipated to become a cornerstone of the next generation of tumor immunotherapy, driving up 3SBIO's stock price. Based on increased competition, the target price has slightly decreased to 37.43 yuan, maintaining a "Buy" rating

AASTOCKS·
SH
520880
-2.45%
SZ
159316
-2.10%
HK
01530
-2.59%
AASTOCKS·
SH
520880
-2.45%
SZ
159316
-2.10%
HK
01530
-2.59%

The Hang Seng Index fell 0.1% at midday, and the Hang Seng TECH Index dropped 0.4%

36Kr learned that the Hang Seng Index fell 0.1% during the midday break, and the Hang Seng TECH Index dropped 0.4%; the non-ferrous metals, pharmaceutical and biotechnology, and software services sectors led the decline, with Hong Kong Exchanges and Clearing falling over 5%, 3SBIO dropping over 4%, and XUNCE falling over 4%; the energy, durable consumer goods, and building materials sectors strengthened, with WISON ENGRG rising over 7%, POP MART and ARTGO HOLDINGS increasing over 1%; southbound funds net bought HKD 3.955 billion

36Kr·
HK
STECH
-2.10%
HK
01530
-2.59%
HK
03313
-0.68%
36Kr·
HK
STECH
-2.10%
HK
01530
-2.59%
HK
03313
-0.68%

Morning Trend | 3SBIO declines on reduced volume, is the support defense battle about to begin?

As of the close on January 21, 3SBIO (1530.HK) continued to oscillate downward, with trading volume consistently shrinking during the session. The main funds showed a strong wait-and-see sentiment, and the strength to seize rebounds was limited. The daily MACD death cross pattern continued, with green bars expanding, making it difficult to reverse the weak pattern in the short term. Overall, the dominant market sentiment remains defensive, with most short-term funds choosing to enter and exit quickly, showing a clear lack of willingness to sustain long positions. In terms of the industry, the biopharmaceutical sector has recently performed weakly, with the uncertainty of price reductions from medical insurance centralized procurement and adjustments to the new medical insurance catalog increasing pressure on growth-oriented pharmaceutical companies. 3SBIO has recently lacked new product approvals or significant business developments, and the company's news flow has been bland, leading to a further decrease in market attention. The overall sector is not very active, and many institutional investors are taking a wait-and-see approach, with defensive sentiment dominating. From the market perspective, CNY 23.58 has become a key level of divergence between bulls and bears. A short-term breach could indicate a second bottoming signal. A decline on shrinking volume typically indicates that active selling is nearing a phase of completion; however, if subsequent volume cannot recover, the downward inertia will still prevail. In terms of intraday performance, there has been some inflow of funds attempting to seize rebounds, but there is a lack of supporting follow-up buying, raising doubts about sustainability. In terms of strategy, it is recommended to keep short-term risk exposure at a low level and closely monitor the trends in medical insurance policies and changes in sector funding. Currently, there are no clear reversal signals from either the technical or fundamental perspectives, and right-side trading users should remain cautious and not increase positions against the trend. Only significant positive news, such as new drug approvals or a notable recovery in trading volume, is likely to bring about a phase of rebound opportunities

Technical Forecast·
HK
01530
-2.59%
Technical Forecast·
HK
01530
-2.59%
Posts
View More
© 2026 Longbridge｜Disclaimer